Development and validation of the composite asthma severity index - An outcome measure for use in children and adolescents

Jeremy J. Wildfire, Peter J. Gergen, Christine A. Sorkness, Herman E. Mitchell, Agustin Calatroni, Meyer Kattan, Stanley J. Szefler, Stephen J. Teach, Gordon R. Bloomberg, Robert A. Wood, Andrew H. Liu, Jacqueline A. Pongracic, James F. Chmiel, Kathleen Conroy, Yadira Rivera-Sanchez, William W. Busse, Wayne J. Morgan

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background: Asthma severity is reflected in many aspects of the disease, including impairment and future risks, particularly for exacerbations. According to the Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, however, to assess more comprehensively the severity of asthma the level of current treatment needed to maintain a level of control should be included. Objective: Development and validation of a new instrument, the Composite Asthma Severity Index (CASI), which can quantify disease severity by taking into account impairment, risk, and the amount of medication needed to maintain control. At present, there is no instrument available to measure and assess the multidimensional nature of asthma. Methods: Twenty-six established asthma investigators, who are part of the National Institutes of Health-supported Inner City Asthma Consortium, participated in a modified Delphi consensus process to identify and weight the dimensions of asthma. Factor analysis was performed to identify independent domains of asthma by using the Asthma Control Evaluation trial. CASI was validated by using the Inner City Anti-IgE Therapy for Asthma trial. Results: CASI scores include 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations. At Asthma Control Evaluation trial enrollment, CASI ranged from 0 to 17, with a mean of 6.2. CASI was stable, with minimal change in variance after 1 year of treatment. In external validation, CASI detected a 32% larger improvement than did symptoms alone. Conclusion: CASI retained its discriminatory ability even with low levels of symptoms reported after months of guidelines-directed care. Thus, CASI has the ability to determine the level of asthma severity and provide a composite clinical characterization of asthma.

Original languageEnglish (US)
Pages (from-to)694-701
Number of pages8
JournalJournal of Allergy and Clinical Immunology
Volume129
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Asthma
Outcome Assessment (Health Care)
Albuterol
Guidelines
National Institutes of Health (U.S.)
Therapeutics
Statistical Factor Analysis

Keywords

  • Asthma
  • composite score
  • exacerbations
  • morbidity
  • severity
  • symptoms
  • treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Wildfire, J. J., Gergen, P. J., Sorkness, C. A., Mitchell, H. E., Calatroni, A., Kattan, M., ... Morgan, W. J. (2012). Development and validation of the composite asthma severity index - An outcome measure for use in children and adolescents. Journal of Allergy and Clinical Immunology, 129(3), 694-701. https://doi.org/10.1016/j.jaci.2011.12.962

Development and validation of the composite asthma severity index - An outcome measure for use in children and adolescents. / Wildfire, Jeremy J.; Gergen, Peter J.; Sorkness, Christine A.; Mitchell, Herman E.; Calatroni, Agustin; Kattan, Meyer; Szefler, Stanley J.; Teach, Stephen J.; Bloomberg, Gordon R.; Wood, Robert A.; Liu, Andrew H.; Pongracic, Jacqueline A.; Chmiel, James F.; Conroy, Kathleen; Rivera-Sanchez, Yadira; Busse, William W.; Morgan, Wayne J.

In: Journal of Allergy and Clinical Immunology, Vol. 129, No. 3, 03.2012, p. 694-701.

Research output: Contribution to journalArticle

Wildfire, JJ, Gergen, PJ, Sorkness, CA, Mitchell, HE, Calatroni, A, Kattan, M, Szefler, SJ, Teach, SJ, Bloomberg, GR, Wood, RA, Liu, AH, Pongracic, JA, Chmiel, JF, Conroy, K, Rivera-Sanchez, Y, Busse, WW & Morgan, WJ 2012, 'Development and validation of the composite asthma severity index - An outcome measure for use in children and adolescents', Journal of Allergy and Clinical Immunology, vol. 129, no. 3, pp. 694-701. https://doi.org/10.1016/j.jaci.2011.12.962
Wildfire, Jeremy J. ; Gergen, Peter J. ; Sorkness, Christine A. ; Mitchell, Herman E. ; Calatroni, Agustin ; Kattan, Meyer ; Szefler, Stanley J. ; Teach, Stephen J. ; Bloomberg, Gordon R. ; Wood, Robert A. ; Liu, Andrew H. ; Pongracic, Jacqueline A. ; Chmiel, James F. ; Conroy, Kathleen ; Rivera-Sanchez, Yadira ; Busse, William W. ; Morgan, Wayne J. / Development and validation of the composite asthma severity index - An outcome measure for use in children and adolescents. In: Journal of Allergy and Clinical Immunology. 2012 ; Vol. 129, No. 3. pp. 694-701.
@article{635389f4f74a445f9eb3b427755a86f4,
title = "Development and validation of the composite asthma severity index - An outcome measure for use in children and adolescents",
abstract = "Background: Asthma severity is reflected in many aspects of the disease, including impairment and future risks, particularly for exacerbations. According to the Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, however, to assess more comprehensively the severity of asthma the level of current treatment needed to maintain a level of control should be included. Objective: Development and validation of a new instrument, the Composite Asthma Severity Index (CASI), which can quantify disease severity by taking into account impairment, risk, and the amount of medication needed to maintain control. At present, there is no instrument available to measure and assess the multidimensional nature of asthma. Methods: Twenty-six established asthma investigators, who are part of the National Institutes of Health-supported Inner City Asthma Consortium, participated in a modified Delphi consensus process to identify and weight the dimensions of asthma. Factor analysis was performed to identify independent domains of asthma by using the Asthma Control Evaluation trial. CASI was validated by using the Inner City Anti-IgE Therapy for Asthma trial. Results: CASI scores include 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations. At Asthma Control Evaluation trial enrollment, CASI ranged from 0 to 17, with a mean of 6.2. CASI was stable, with minimal change in variance after 1 year of treatment. In external validation, CASI detected a 32{\%} larger improvement than did symptoms alone. Conclusion: CASI retained its discriminatory ability even with low levels of symptoms reported after months of guidelines-directed care. Thus, CASI has the ability to determine the level of asthma severity and provide a composite clinical characterization of asthma.",
keywords = "Asthma, composite score, exacerbations, morbidity, severity, symptoms, treatment",
author = "Wildfire, {Jeremy J.} and Gergen, {Peter J.} and Sorkness, {Christine A.} and Mitchell, {Herman E.} and Agustin Calatroni and Meyer Kattan and Szefler, {Stanley J.} and Teach, {Stephen J.} and Bloomberg, {Gordon R.} and Wood, {Robert A.} and Liu, {Andrew H.} and Pongracic, {Jacqueline A.} and Chmiel, {James F.} and Kathleen Conroy and Yadira Rivera-Sanchez and Busse, {William W.} and Morgan, {Wayne J.}",
year = "2012",
month = "3",
doi = "10.1016/j.jaci.2011.12.962",
language = "English (US)",
volume = "129",
pages = "694--701",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Development and validation of the composite asthma severity index - An outcome measure for use in children and adolescents

AU - Wildfire, Jeremy J.

AU - Gergen, Peter J.

AU - Sorkness, Christine A.

AU - Mitchell, Herman E.

AU - Calatroni, Agustin

AU - Kattan, Meyer

AU - Szefler, Stanley J.

AU - Teach, Stephen J.

AU - Bloomberg, Gordon R.

AU - Wood, Robert A.

AU - Liu, Andrew H.

AU - Pongracic, Jacqueline A.

AU - Chmiel, James F.

AU - Conroy, Kathleen

AU - Rivera-Sanchez, Yadira

AU - Busse, William W.

AU - Morgan, Wayne J.

PY - 2012/3

Y1 - 2012/3

N2 - Background: Asthma severity is reflected in many aspects of the disease, including impairment and future risks, particularly for exacerbations. According to the Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, however, to assess more comprehensively the severity of asthma the level of current treatment needed to maintain a level of control should be included. Objective: Development and validation of a new instrument, the Composite Asthma Severity Index (CASI), which can quantify disease severity by taking into account impairment, risk, and the amount of medication needed to maintain control. At present, there is no instrument available to measure and assess the multidimensional nature of asthma. Methods: Twenty-six established asthma investigators, who are part of the National Institutes of Health-supported Inner City Asthma Consortium, participated in a modified Delphi consensus process to identify and weight the dimensions of asthma. Factor analysis was performed to identify independent domains of asthma by using the Asthma Control Evaluation trial. CASI was validated by using the Inner City Anti-IgE Therapy for Asthma trial. Results: CASI scores include 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations. At Asthma Control Evaluation trial enrollment, CASI ranged from 0 to 17, with a mean of 6.2. CASI was stable, with minimal change in variance after 1 year of treatment. In external validation, CASI detected a 32% larger improvement than did symptoms alone. Conclusion: CASI retained its discriminatory ability even with low levels of symptoms reported after months of guidelines-directed care. Thus, CASI has the ability to determine the level of asthma severity and provide a composite clinical characterization of asthma.

AB - Background: Asthma severity is reflected in many aspects of the disease, including impairment and future risks, particularly for exacerbations. According to the Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, however, to assess more comprehensively the severity of asthma the level of current treatment needed to maintain a level of control should be included. Objective: Development and validation of a new instrument, the Composite Asthma Severity Index (CASI), which can quantify disease severity by taking into account impairment, risk, and the amount of medication needed to maintain control. At present, there is no instrument available to measure and assess the multidimensional nature of asthma. Methods: Twenty-six established asthma investigators, who are part of the National Institutes of Health-supported Inner City Asthma Consortium, participated in a modified Delphi consensus process to identify and weight the dimensions of asthma. Factor analysis was performed to identify independent domains of asthma by using the Asthma Control Evaluation trial. CASI was validated by using the Inner City Anti-IgE Therapy for Asthma trial. Results: CASI scores include 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations. At Asthma Control Evaluation trial enrollment, CASI ranged from 0 to 17, with a mean of 6.2. CASI was stable, with minimal change in variance after 1 year of treatment. In external validation, CASI detected a 32% larger improvement than did symptoms alone. Conclusion: CASI retained its discriminatory ability even with low levels of symptoms reported after months of guidelines-directed care. Thus, CASI has the ability to determine the level of asthma severity and provide a composite clinical characterization of asthma.

KW - Asthma

KW - composite score

KW - exacerbations

KW - morbidity

KW - severity

KW - symptoms

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84857796207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857796207&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2011.12.962

DO - 10.1016/j.jaci.2011.12.962

M3 - Article

VL - 129

SP - 694

EP - 701

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -